PIERIS PHARMACEUTICALS INC's ticker is PIRS and the CUSIP is 720795103. A total of 114 filers reported holding PIERIS PHARMACEUTICALS INC in Q2 2018. The put-call ratio across all filers is 45.62 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2024 | $3,775,727 | +0.7% | 20,609,863 | 0.0% | 0.10% | +10.6% |
Q4 2023 | $3,750,995 | -38.9% | 20,609,863 | 0.0% | 0.09% | -43.4% |
Q3 2023 | $6,141,739 | +80.1% | 20,609,863 | 0.0% | 0.17% | +74.7% |
Q2 2023 | $3,410,932 | -31.2% | 20,609,863 | +305.7% | 0.10% | -47.5% |
Q1 2023 | $4,958,392 | -6.2% | 5,080,320 | 0.0% | 0.18% | -18.8% |
Q4 2022 | $5,283,533 | -9.6% | 5,080,320 | 0.0% | 0.22% | -7.5% |
Q3 2022 | $5,842,000 | -38.5% | 5,080,320 | 0.0% | 0.24% | -47.5% |
Q2 2022 | $9,500,000 | -41.2% | 5,080,320 | -4.7% | 0.46% | -28.9% |
Q1 2022 | $16,145,000 | -19.8% | 5,328,239 | 0.0% | 0.65% | -11.6% |
Q4 2021 | $20,141,000 | -26.9% | 5,328,239 | 0.0% | 0.73% | -32.0% |
Q3 2021 | $27,547,000 | +35.0% | 5,328,239 | 0.0% | 1.08% | +40.5% |
Q2 2021 | $20,407,000 | +44.5% | 5,328,239 | -3.0% | 0.76% | +44.6% |
Q1 2021 | $14,121,000 | +2.8% | 5,494,582 | 0.0% | 0.53% | -2.0% |
Q4 2020 | $13,736,000 | +20.8% | 5,494,582 | 0.0% | 0.54% | -12.8% |
Q3 2020 | $11,374,000 | +17.8% | 5,494,582 | +76.4% | 0.62% | +4.0% |
Q2 2020 | $9,658,000 | -27.9% | 3,115,382 | -47.0% | 0.60% | -52.3% |
Q1 2020 | $13,390,000 | -30.9% | 5,872,762 | +9.8% | 1.25% | -15.0% |
Q4 2019 | $19,367,000 | +6.2% | 5,349,905 | 0.0% | 1.47% | -23.4% |
Q3 2019 | $18,243,000 | -1.8% | 5,349,905 | +35.3% | 1.92% | -5.6% |
Q2 2019 | $18,585,000 | +36.7% | 3,954,264 | -2.6% | 2.03% | +33.4% |
Q1 2019 | $13,596,000 | -31.5% | 4,058,385 | -45.6% | 1.52% | -41.3% |
Q4 2018 | $19,838,000 | -36.7% | 7,457,921 | +33.2% | 2.59% | -5.9% |
Q3 2018 | $31,363,000 | +15.7% | 5,600,521 | +4.7% | 2.76% | +4.2% |
Q2 2018 | $27,108,000 | +10.6% | 5,346,838 | +48.8% | 2.65% | +6.5% |
Q1 2018 | $24,501,000 | +23.7% | 3,592,549 | +36.9% | 2.48% | +4.0% |
Q4 2017 | $19,808,000 | +15.1% | 2,623,562 | -12.2% | 2.39% | +9.2% |
Q3 2017 | $17,203,000 | -2.6% | 2,986,562 | -14.5% | 2.19% | -20.3% |
Q2 2017 | $17,669,000 | +254.5% | 3,491,933 | +82.2% | 2.74% | +223.6% |
Q1 2017 | $4,984,000 | +91.3% | 1,917,033 | +3.4% | 0.85% | +61.8% |
Q4 2016 | $2,606,000 | +40.3% | 1,854,768 | +82.4% | 0.52% | +49.7% |
Q3 2016 | $1,858,000 | +377.6% | 1,016,593 | +321.2% | 0.35% | +321.7% |
Q2 2016 | $389,000 | – | 241,352 | – | 0.08% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Prosight Management, LP | 1,360,000 | $6,895,000 | 5.06% |
Omega Fund Management, LLC | 778,230 | $3,946,000 | 2.91% |
BVF INC/IL | 5,346,838 | $27,108,000 | 2.65% |
Virtus ETF Advisers LLC | 152,550 | $773,000 | 0.68% |
SPHERA FUNDS MANAGEMENT LTD. | 842,632 | $4,272,000 | 0.59% |
Tekla Capital Management LLC | 2,087,380 | $10,583,000 | 0.40% |
Schonfeld Strategic Advisors LLC | 828,600 | $4,201,000 | 0.23% |
Orbimed Advisors | 3,140,000 | $15,920,000 | 0.19% |
Lombard Odier Asset Management (USA) Corp | 563,878 | $2,859,000 | 0.19% |
Rhenman & Partners Asset Management AB | 300,000 | $1,521,000 | 0.16% |